Cancer Research Audrey Hepburn Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moser, A. R.
Right arrow Articles by Cardiff, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moser, A. R.
Right arrow Articles by Cardiff, R. D.
[Cancer Research 61, 3480-3485, April 15, 2001]
© 2001 American Association for Cancer Research

Tumor Biology

Genetic Background Affects Susceptibility to Mammary Hyperplasias and Carcinomas in ApcMin/+ Mice1

Amy Rapaich Moser2, Laura F. Hegge and Robert D. Cardiff

Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin 53792 [A. R. M., L. F. H.], and Center for Comparative Medicine, University of California-Davis, Davis, California 95616 [R. D. C.]

Treatment of female C57BL/6J (B6) mice carrying the mutant Min allele of the adenomatous polyposis coli (Apc) gene with ethylnitrosourea (ENU) results in ~90% of mice developing an average of three mammary tumors within 65 days. As a first step in the identification of loci modifying susceptibility to ENU-induced mammary tumors and hyperplasias, we have tested ENU-treated ApcMin/+ (Min/+) mice on several hybrid backgrounds for susceptibility to mammary and intestinal tumors. C57BR/cdJxB6 (BRB6) Min/+ mice were more sensitive to development of mammary squamous cell carcinomas than B6 Min/+ mice. In contrast, Min/+ hybrids between B6 and FVB/NTac (FVB), 129X1/SvJ (129X1), and 129S6/SvEvTac (129S6) were all significantly more resistant to mammary carcinoma development. However, mice from these three crosses developed more focal mammary hyperplasias than did the B6 or BRB6 Min/+ mice. Susceptibility to intestinal tumors was independent of mammary tumor susceptibility in most hybrids. These results indicate that genetic background can affect independently the phenotypes conferred by the Min allele of Apc.




This article has been cited by other articles:


Home page
 CarcinogenesisHome page
M. J. Sinnamon, K. J. Carter, L. P. Sims, B. LaFleur, B. Fingleton, and L. M. Matrisian
A protective role of mast cells in intestinal tumorigenesis
Carcinogenesis, April 1, 2008; 29(4): 880 - 886.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
N. M. Ramocki, H. R. Wilkins, S. T. Magness, J. G. Simmons, B. P. Scull, G. H. Lee, K. K. McNaughton, and P. K. Lund
Insulin Receptor Substrate-1 Deficiency Promotes Apoptosis in the Putative Intestinal Crypt Stem Cell Region, Limits Apcmin/+ Tumors, and Regulates Sox9
Endocrinology, January 1, 2008; 149(1): 261 - 267.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Wang, D. Teske, A. Tess, R. Kohlhepp, Y. Choi, C. Kendziorski, and A. R. Moser
Identification of Novel Modifier Loci of ApcMin Affecting Mammary Tumor Development
Cancer Res., December 1, 2007; 67(23): 11226 - 11233.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. Tong, Z. Yin, Z. Song, A. Dockendorff, C. Huang, J. Mariadason, R. A. Flavell, R. J. Davis, L. H. Augenlicht, and W. Yang
c-Jun NH2-Terminal Kinase 1 Plays a Critical Role in Intestinal Homeostasis and Tumor Suppression
Am. J. Pathol., July 1, 2007; 171(1): 297 - 303.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. E. Talmadge, R. K. Singh, I. J. Fidler, and A. Raz
Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for Cancer
Am. J. Pathol., March 1, 2007; 170(3): 793 - 804.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
M. P.V. Shekhar, L. Tait, and B. Gerard
Essential Role of T-Cell Factor/{beta}-Catenin in Regulation of Rad6B: A Potential Mechanism for Rad6B Overexpression in Breast Cancer Cells
Mol. Cancer Res., October 1, 2006; 4(10): 729 - 745.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Czarnomska, E. Krysiak, J. Piskorowska, M. Sitarz, K. Pysniak, T. Pilcik, and P. Demant
Opposite Effects of Modifiers of the ApcMin Mutation in Intestine and Mammary Gland
Cancer Res., August 1, 2003; 63(15): 4533 - 4537.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. Rosner, K. Miyoshi, E. Landesman-Bollag, X. Xu, D. C. Seldin, A. R. Moser, C. L. MacLeod, G. Shyamala, A. E. Gillgrass, and R. D. Cardiff
Pathway Pathology : Histological Differences Between ErbB/Ras and Wnt Pathway Transgenic Mammary Tumors
Am. J. Pathol., September 1, 2002; 161(3): 1087 - 1097.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.